Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686977 | 0.94 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2C9NPC1APEX1 | |
| SCHEMBL31667561 | 0.89 | NPC1 (0.37) | CYP1A2CYP3A4CYP2C9NPC1KDM4E | |
| SCHEMBL32686812 | 0.88 | MIF (0.41) | NPC1MIFTNIK | |
| SCHEMBL31667152 | 0.86 | NPC1 (0.46) | CYP1A2CYP3A4CYP2C9NPC1MIF | |
| SCHEMBL32686876 | 0.86 | TNIK (0.36) | NPC1MIFTNIKALDH1A1 | |
| SCHEMBL32686773 | 0.86 | NPC1 (0.39) | NPC1MIFTNIKALDH1A1 | |
| SCHEMBL32686867 | 0.86 | MEN1 (0.32) | NPC1MIFTNIK | |
| SCHEMBL32686786 | 0.85 | SMN1; SMN2 (0.35) | CYP1A2CYP3A4CYP2C9NPC1KDM4E | |
| SCHEMBL32686731 | 0.84 | MIF (0.39) | CYP1A2CYP3A4CYP2C9NPC1MIF | |
| SCHEMBL31667236 | 0.84 | NPC1 (0.37) | NPC1KDM4EMIFTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | CYP1A2 1868/4885CYP3A4 2054/4885CYP2C9 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.